Table 1 Characteristics of the CUtLASS cognitive study sample at trial entry
| Â | Mean (SD) | Range |
|---|---|---|
Age (years) | 41.9 (12.0) | 22–67 |
Duration of illness (years) | 16.5 (12.0) | 1–46 |
PANSS Positive symptoms | 16.6 (6.92) | 7–37 |
PANSS Negative symptoms | 22.0 (7.58) | 7–42 |
PANSS General symptoms | 34.5 (8.66) | 7–56 |
Global Assessment of Function | 43.3 (15.0) | 17–66 |
NART premorbid IQ | 105.6 (12.3) | 87–123 |
Drug allocations | FGA (n) | SGA (n) |
| Â | Droperidol (1) | Clozapine (14) |
| Â | Haloperidol (2) | Quetiapine (4) |
| Â | Sulpiride (10) | Risperidone (4) |
| Â | Thioridazine (1) | Olanzapine (19) |
| Â | Trifluoperazine (2) | Â |
| Â | Zuclopenthixol (1) | Â |